Biological treatments currently approved for IBD treatment in Europe include anti-tumour necrosis factor (TNF) therapies (infliximab, adalimumab, and golimumab), anti-IL-12/23 agents (ustekinumab), and anti-integrin agents (vedolizumab) [15–19]. Here, TNF is linked to inflammatory bowel disease.